Medication and nutritional supplement use before and after bariatric surgery
Keywords:
Bariatric surgery, Comorbidity, Pharmaceutical preparations, Gastric bypass, Obesity, morbidAbstract
CONTEXT AND OBJECTIVE: Bariatric surgery has been an effective alternative treatment for morbid obesity and has resulted in decreased mortality, better control over comorbidities and reduced use of drugs. The objective of this study was to analyze the impact of bariatric surgery on medication drug and nutritional supplement use. DESIGN AND SETTING: Longitudinal study of before-and-after type, on 69 morbidly obese patients in a public hospital in Porto Alegre. METHODS: Through interviews, the presence of comorbidities and use of drugs with and without prescription were evaluated. RESULTS: Among the 69 patients interviewed, 85.5% had comorbidities in the preoperative period, with an average of 2.3 (± 1.5) per patient. The main comorbidities reported were hypertension, diabetes and dyslipidemia. 84.1% of the patients were using prescribed drugs in the preoperative period. The mean drug use per patient was 4.8, which decreased to 4.4 after the procedure. The surgery enabled significant reduction in use of most antidiabetic (84%), antilipemic (77%) and antihypertensive drugs (49.5%). On the other hand, there was a significant increase in use of multivitamins and drugs for disorders of the gastrointestinal tract. The dosages of most of the drugs that continued to be prescribed after surgery were decreased, but not significantly. CONCLUSION: After bariatric surgery, there were increases in the use of vitamins, gastric antisecretory drugs and antianemic drugs. Nevertheless, there was an overall reduction in drug use during this period, caused by suspension of drugs or dose reduction.
Downloads
References
Brasil. Ministério da Saúde. Vigitel Brasil 2013 – Vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico. Brasília: Ministério da Saúde; 2014. Available from: http://www.prefeitura.sp.gov.br/cidade/secretarias/upload/saude/arquivos/morbidade/Vigitel-2013.pdf. Accessed in 2016 (Jun 2).
World Health Organization. Obesity and overweight. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html. Accessed in 2016 (Jun 2).
Barja-Fernandez S, Leis R, Casanueva FF, Seoane LM. Drug development strategies for the treatment of obesity: how to ensure efficacy, safety, and sustainable weight loss. Drug Des Devel Ther. 2014;8:2391-400.
McTigue KM, Harris R, Hemphill B, et al. Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2003;139(11):933-49.
Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta- analysis. BMC Public Health. 2009;9:88.
Blüher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diab. 2009;117:241-50.
Baretić M. Obesity drug therapy. Minerva Endocrinol. 2013; 38(3):245-54.
Kissler HJ, Settmacher U. Bariatric surgery to treat obesity. Semin Nephrol. 2013;33(1):75-89.
Gelber RP, Gaziano JM Manson JE, Buring JE, Sesso HD. A prospective study of body mass index and the risk of developing hypertension in men. Am J Hypertens. 2007;20(4):370-7.
Piché ME, Auclair A, Harvey J, Marceau S, Poirier P. How to choose and use bariatric surgery in 2015. Can J Cardiol. 2015;31(2):153-66.
Geraldo M de S, Fonseca FL, Gouveia MR, Feder D. The use of drugs in patients who have undergone bariatric surgery. Int J Gen Med. 2014;7:219-24.
Xu XJ, Apovian C, Hess D, et al. Improved Insulin Sensitivity 3 Months After RYGB Surgery is Associated With Increased Subcutaneous Adipose Tissue AMPK Activity and Decreased Oxidative Stress. Diabetes. 2015;64(9):3155-9.
Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219-34.
Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724-37.
Gould JC, Garren MJ, Starling JR. Laparoscopic gastric bypass results in decreased prescription medication costs within 6 months. J Gastrointest Surg. 2004;8(8):983-7.
Nguyen NT, Varela JE, Sabio A, et al. Reduction in prescription medication costs after laparoscopic gastric bypass. Am Surg. 2006;72(10):853-6.
Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683-93.
Benaiges D, Goday A, Ramon JM, et al. Laparoscopic sleeve gastrectomy and laparoscopic gastric bypass are equally effective for reduction of cardiovascular risk in severely obese patients at one year of follow-up. Surg Obes Relat Dis. 2011;7(5):575-80.
Kwok CS, Pradhan A, Khan MA, et al. Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis. Int J Cardiol. 2014;173(1):20-8.
Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long- term cardiovascular events. JAMA. 2012;307(1):56-65.
Malone M, Alger-Mayer S, Lindstrom J, Bailie GR. Management of iron deficiency and anemia after Roux-en-Y gastric bypass surgery: an observational study. Surg Obes Relat Dis. 2013;9(6):969-74.
Brasil. Ministério da Saúde. Gabinete do Ministro. Portaria no 424, de 19 de março de 2013. Redefine as diretrizes para a organização da prevenção e do tratamento do sobrepeso e obesidade como linha de cuidado prioritária da Rede de Atenção à Saúde das Pessoas com Doenças Crônicas. Brasília, 2013. Available from: http://bvsms.saude.gov.br/bvs/saudelegis/gm/2013/prt0424_19_03_2013.html. Accessed in 2016 (Jun 2).
National Institute of Health. Bariatric surgery for severe obesity. Weight-control Information Network; 2011. Available from: http:// win.niddk.nih.gov/publications/PDFs/Bariatric_Surgery_508.pdf. Accessed in 2016 (Jun 2).
Conselho Federal de Medicina. Resolução CFM no 1.942/2010. Normas seguras para o tratamento cirúrgico da obesidade mórbida, definindo indicações, procedimentos e equipe. Publicada no D. O.
U. de 12 de fevereiro de 2010, Seção I, p. 72. Available from: http:// www.portalmedico.org.br/resolucoes/CFM/2010/1942_2010.htm. Accessed in 2016 (Jun 2).
Snow LL, Weinstein LS, Hannon JK, et al. The effect of Roux-en-Y gastric bypass on prescription drug costs. Obes Surg. 2004;14(8):1031-5.
Maciejewski ML, Livingston EH, Kahwati LC, et al. Discontinuation of diabetes and lipid-lowering medications after bariatric surgery at Veterans Affairs medical centers. Surg Obes Rel Dis. 2010;6(6):601-7.
Potteiger CE, Paragi PR, Inverso NA, et al. Bariatric surgery: shedding the monetary weight of prescription costs in the managed care arena. Obes Surg. 2004;14(6):725-30.
Narbro K, Agren G, Jonsson E, et al. Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study. Arch Intern Med. 2002;162(18):2061-9.
Lopes EC, Heineck I, Athaydes G, et al. Is Bariatric Surgery Effective in Reducing Comorbidities and Drug Costs? A Systematic Review and Meta-Analysis. Obes Surg. 2015;25(9):1741-9.
Yu J, Zhou X, Li L, et al. The long-term effects of bariatric surgery for type 2 diabetes: systematic review and meta-analysis of randomized and non-randomized evidence. Obes Surg. 2014;25(1):143-58.
Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248-256.e5.
Garrido-Sanchez L, Murri M, Rivas-Becerra J, et al. Bypass of the duodenum improves insulin resistance much more rapidly than sleeve gastrectomy. Surg Obes Relat Dis. 2012;8(2):145-50.
Pories WJ, Mehaffey JH, Staton KM. The surgical treatment of type two diabetes mellitus. Surg Clin North Am. 2011;91(4):821-36, viii.
Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567-76.
Laferrère B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30(7):1709-16.
Aron-Wisnewsky J, Clement K. The effects of gastrointestinal surgery on gut microbiota: potential contribution to improved insulin sensitivity. Curr Atheroscler Rep. 2014;16(11):454.
Simonen M, Dali-Youcef N, Kaminska D, et al. Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux- en-Y gastric bypass. Obes Surg. 2012;22(9):1473-80.
Kohli R, Bradley D, Setchell KD, et al. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab. 2013;98(4):E708-12.
Bhutta HY, Raipal N, White W, et al. Effect of Roux-en-Y gastric bypass surgery on bile acid metabolism in normal and obese diabetic rats. PLos One. 2015;10(3):e0122273.
Kashyap SR, Gatmaitan P, Brethauer S, Schauer P. Bariatric surgery for type 2 diabetes: weighing the impact for obese patients. Cleve Clin J Med. 2010;77(7):468-76.
Rhee NA, Vilsbøll T, Knop FK. Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes. Diabetes Obes Metab. 2012;14(4):291-8.
Neff KJ, O’Shea D, Ie Roux CW. Glucagon like peptide-1 (GLP-1) dynamics following bariatric surgery: a Signpost to a new frontier. Curr Diabetes Rev. 2013;9(2):93-101.
American Society of Health-System Pharmacists. AHFS: Drug information. Bethesda: ASHP; 2014.
Aron-Wisnewsky J, Lemaitre F, Clément K, et al. Pharmacokinetics of immunomodulator treatments after roux-en-y bypass in obese patient. J Clin Pharmacol. 2013;53(7):779-84.
Oria HE, Moorehead MK. Bariatric analysis and reporting outcome system (BAROS). Obes Surg. 1998;8(5):487-99.
González P JF, Gómez C G, Arriagada P G. Evaluación mediante score Baros de los resultados del bypass gástrico en el tratamiento de la obesidad mórbida [Evaluation of gastric bypass surgery using the Baros score]. Rev Chil Cir. 2006;58(5):365-70.
Vest AR, Heneghan HM, Agarwal S, Schauer PR, Young JB. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart. 2012;98(24):1763-77.
Ricci NA, Pessoa GS, Ferriolli E, Dias RC, Perracini MR. Frailty and cardiovascular risk in community-dwelling elderly: a population- based study. Clin Interv Aging. 2014;9:1677-85.
Hinojosa MW, Varela JE, Smith BR, Che F, Nguyen NT. Resolution of systemic hypertension after laparoscopic gastric bypass. J Gastrointest Surg. 2009;13(4):793-7.
Pajecki D, Dalcanalle L, Souza de Oliveira CP, et al. Follow-up of Roux- en-Y gastric bypass patients at 5 or more years postoperatively. Obes Surg. 2007;17(5):601-7.
Masuo K, Mikami H, Ogihara T, Tuck ML. Differences in mechanisms between weight loss-sensitive and -resistant blood pressure reduction in obese subjects. Hypertens Res. 2001;24(4):371-6.
Reisin E, Frohlich ED, Messerli FH, et al. Cardiovascular changes after weight reduction in obesity hypertension. Ann Intern Med. 1983;98(3):315-9.
Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma rennin activity, and plasma aldosterone levels in obese patients. N Engl J Med. 1981;304(16):930-3.
Dixon JB, O’Brien PE. Lipid profile in the severely obese: changes with weight loss after lap-band surgery. Obes Res. 2002;10(9):903-10.
Crémieux P, Ledoux S, Clerici C, Cremieux F, Buessing M. The impact of bariatric surgery on comorbidities and medication use among patients. Obes Surg. 2010;20(7):861-70.
Pournaras DJ, Ie Roux CW. After bariatric surgery, what vitamins should be measured and what supplements should be given? Clin Endocrinol (Oxf ). 2009;71(3):322-5.
Miller AD, Smith KM. Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm. 2006;63(19):1852-7.
Ravelli MN, Merhi VAL, Mônaco DV, Aranha N. Obesidade, cirurgia bariátrica e implicações nutricionais. Revista Brasileira em Promoção da Saúde. 2007;20(4):259-66. Available from: http://ojs.unifor.br/index.php/RBPS/article/view/1036/2196. Accessed in 2016 (Jun 2).
Gehrer S, Kern B, Peters T, Christofiel-Courtin C, Peterli R. Fewer nutrient deficiencies after laparoscopic sleeve gastrectomy (LSG) than after laparoscopic Roux-Y-gastric bypass (LRYGB)-a prospective study. Obes Surg. 2010;20(4):447-53.
Stein J, Stier C, Raab H, Weiner R. Review article: The nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther. 2014;40(6):582-609.
Reinehr T, Roth CL. The gut sensor as regulator of body weight. Endocrine. 2015;49(1):35-50.
Fontana MA, Wohlgemuth SD. The surgical treatment of metabolic disease and morbid obesity. Gastroenterol Clin North Am. 2010;39(1):125-33.
Rasmussen JJ, Fuller W, Ali MR. Marginal ulceration after laparoscopic gastric bypass: an analysis of predisposing factors in 260 patients. Surg Endosc. 2007;21(7):1090-4.
Sidani S, Akkary E, Bell R. Catastrophic bleeding from a marginal ulcer after gastric bypass. JSLS. 2013;17(1):148-51.
Sapala JA, Wood MH, Sapala MA, Flake TM Jr. Marginal ulcer after gastric bypass: a prospective 3-year study of 173 patients. Obes Surg. 1998;8(5):505-16.
D’Hondt MA, Pottel H, Devriendt D, Van Rooy F, Vansteenkiste F. Can a short course of prophylactic low-dose proton pump inhibitor therapy prevent stomal ulceration after laparoscopic Roux-en-Y gastric bypass? Obes Surg. 2010;20(5):595-9.
Sanyal AJ, Sugerman HJ, Kellum JM, Engle KM, Wolfe L. Stomal complications of gastric bypass: incidence and outcome of therapy. Am J Gastroenterol. 1992;87(9):1165-9.
Jordan WH, Hocking MP, Rout WR, Woodward ER. Marginal ulcer following gastric bypass for morbid obesity. Am Surg. 1991;57(5):286-8.
Pope GD, Goodney PP, Burchard KW, et al. Peptic ulcer/stricture after gastric bypass: a comparison of technique and acid suppression variables. Obes Surg. 2002;12(1):30-3.
Lopes EC. Impacto da cirurgia bariátrica na qualidade de vida e nos gastos com medicamentos em uma população de usuários do SUS [thesis]. Porto Alegre: Universidade Federal do Rio Grande do Sul; 2013.
Segal JB, Clark JM, Shore AD, et al. Prompt reduction in use of medications for comorbid conditions after bariatric surgery. Obes Surg. 2009;19(12):1646-56.
Fandiño J, Benchimol AK, Coutinho WF, Appolinário JC. Cirurgia bariátrica: aspectos clínico-cirúrgicos e psiquiátricos [Bariatric surgery: clinical, surgical and psychiatric aspects]. Rev Psiquiatr Rio Gd Sul. 2004;26(1):47-51.
Kodama K, Noda S, Murakami A, et al. Depressive disorders as psychiatric complications after obesity surgery. Psychiatry Clin Neurosci. 1998;52(5):471-6.
Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222(3):339-50; discussion 350-2.
Capella JF, Capella RF. The weight reduction operation of choice: vertical banded gastroplasty or gastric bypass. Am J Surg. 1996;171(1):74-9.
van Hout G, van Heck G. Bariatric psychology, psychological aspects of weight loss surgery. Obes Facts. 2009;2(1):10-5.
Matini D, Ghanbari Jolfaei A, Pazouki A, Pishgahroudsari M, Ehtesham
M. The comparison of severity and prevalence of major depressive disorder, general anxiety disorder and eating disorders before and after bariatric surgery. Med J Islam Repub Iran. 2014;28:109.
Peterhänsel C, Wagner B, Dietrich A, Kersting A. Obesity and co- morbid psychiatric disorders as contraindications for bariatric surgery? A case study. Int J Surg Case Rep. 2014;5(12):1268-70.
Frank P, Crookes PF. Short- and long-term surgical follow-up of the postbariatric surgery patient. Gastroenterol Clin North Am. 2010;39(1):135-46.
Dhabuwala A, Cannan RJ, Stubbs RS. Improvement in co-morbidities following weight loss from gastric bypass surgery. Obes Surg. 2000;10(5):428-35.
Hodo DM, Waller JL, Martindale RG, Fick DM. Medication use after bariatric surgery in a managed care cohort. Surg Obes Relat Dis. 2008;4(5):601-7.
Schlienger JL, Pradignac A, Luca F, Meyer L, Rohr S. Medical management of diabetes after bariatric surgery. Diabetes Metab. 2009;35(6 Pt 2):558-61.
